Epilepsia is the leading, authoritative journal for innovative clinical and basic science research for all aspects of epilepsy and seizures. In addition, Epilepsia publishes critical reviews, opinion pieces, and guidelines that foster understanding and aim to improve the diagnosis and treatment of people with seizures and epilepsy.

Journal Metrics

  • 11.4CiteScore
  • 6.6Journal Impact Factor
  • 25%Acceptance rate
  • 14 days Submission to first decision
view all metrics

Reasons to Publish with Us:

  • Enjoy an easy Free Format submission process, with quick first decision time of 3 weeks on average, and Accepted Article publication, getting your research online quicker.
  • Publish with prestige in an ILAE-owned journal, ranked in the JCR's top 10% in Clinical Neurology.
  • Enhance your article visibility in a journal boasting over 2.5 million article downloads annually. 
  • Increased impact via publicity, social media, and publication of landmark papers.

Articles

RESEARCH ARTICLE
Open access

Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant focal epilepsies treated in the Expanded Access Program

  •  17 July 2025

Graphical Abstract

Long-term efficacy and safety of cannabidiol in patients with treatment-resistant focal epilepsies treated in the Expanded Access Program Issue ,

Open-label CBD treatment was associated with sustained seizure reduction through 144 weeks, with a consistent safety profile in patients with treatment-resistant focal epilepsies, regardless of epilepsy type.

More articles

The following is a list of the most cited articles based on citations published in the last three years, according to CrossRef.

More articles

Recent issues

Latest news